229 related articles for article (PubMed ID: 1426667)
1. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
Barreto L; Csizer Z; Sparkes JD
Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
[TBL] [Abstract][Full Text] [Related]
2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
[TBL] [Abstract][Full Text] [Related]
4. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
5. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
[No Abstract] [Full Text] [Related]
6. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
[TBL] [Abstract][Full Text] [Related]
7. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
Lamm DL; Crissmann J; Blumenstein B; Crawford ED; Montie J; Scardino P; Grossman HB; Stanisic T; Smith J; Sullivan J
Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
[No Abstract] [Full Text] [Related]
8. [ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder].
Tsukagoshi S
Gan To Kagaku Ryoho; 2003 Jul; 30(7):1027-38. PubMed ID: 12894724
[TBL] [Abstract][Full Text] [Related]
9. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
10. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
11. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
12. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
13. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
15. [Intravesical BCG vaccine in bladder cancer].
Beisland HO; Sander S
Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
[TBL] [Abstract][Full Text] [Related]
16. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
17. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study.
Mori K; Lamm DL; Crawford ED
Urol Int; 1986; 41(4):254-9. PubMed ID: 3538593
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of intravesical therapy for superficial bladder cancer.
Lamm DL
Urol Clin North Am; 1992 Aug; 19(3):573-80. PubMed ID: 1636241
[TBL] [Abstract][Full Text] [Related]
19. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
20. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]